BRINTELLIX 20 MG İsrail - İngilizce - Ministry of Health

brintellix 20 mg

lundbeck israel ltd. - vortioxetine as hydrobromide - film coated tablets - vortioxetine as hydrobromide 20 mg - vortioxetine - brintellix is indicated for the treatment of major depressive episodes in adults.

BRINTELLIX 20 MG İsrail - İngilizce - Ministry of Health

brintellix 20 mg

lundbeck israel ltd. - vortioxetine as hydrobromide - film coated tablets - vortioxetine as hydrobromide 20 mg - vortioxetine - brintellix is indicated for the treatment of major depressive episodes in adults.

BRINTELLIX 5 MG İsrail - İngilizce - Ministry of Health

brintellix 5 mg

lundbeck israel ltd. - vortioxetine as hydrobromide - film coated tablets - vortioxetine as hydrobromide 5 mg - vortioxetine - brintellix is indicated for the treatment of major depressive episodes in adults.

BRINTELLIX 5 MG İsrail - İngilizce - Ministry of Health

brintellix 5 mg

lundbeck israel ltd. - vortioxetine as hydrobromide - film coated tablets - vortioxetine as hydrobromide 5 mg - vortioxetine - brintellix is indicated for the treatment of major depressive episodes in adults.

SELINCRO 18 MG İsrail - İngilizce - Ministry of Health

selincro 18 mg

lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - film coated tablets - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (drl), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drl two weeks after initial assessment.

SELINCRO 18 MG İsrail - İngilizce - Ministry of Health

selincro 18 mg

lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - film coated tablets - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (drl), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drl two weeks after initial assessment.